Severe COVID-19 is associated with hyperactivation of the alternative complement pathway

Jérémy Boussier; Jérémy Boussier; Nader Yatim; Nader Yatim; A. Marchal; A. Marchal; Jérôme Hadjadj; Jérôme Hadjadj; Bruno Charbit; Bruno Charbit; Carine El Sissy; Carine El Sissy; Nicolas Carlier; Nicolas Carlier; Frédéric Pène; Frédéric Pène; Luc Mouthon; Luc Mouthon; Pierre‐Louis Tharaux; Pierre‐Louis Tharaux; Anne Bergeron; Anne Bergeron; David M. Smadja; David M. Smadja; Frédéric Rieux‐Laucat; Frédéric Rieux‐Laucat; Darragh Duffy; Darragh Duffy; Solen Kernéis; Solen Kernéis; Véronique Frémeaux‐Bacchi; Véronique Frémeaux‐Bacchi; Benjamin Terrier; Benjamin Terrier

doi:10.1016/j.jaci.2021.11.004

Related publications

Article2022

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Valentina Fanny Leone, Amantia Imeraj, Sara Gastoldi, Caterina Mele, Lucia Liguori, Carmelita Condemi, Piero Ruggenenti, Giuseppe Remuzzi, Camillo Carrara

Preprint2022

Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity

Laura Sánchez‐Rivera, Laura Sánchez‐Rivera, María Jesús Iglesias, María Jesús Iglesias, Manal Ibrahim‐Kosta, Manal Ibrahim‐Kosta, Julia B. Kral‐Pointner, Julia B. Kral‐Pointner, Sebastian Havervall, Sebastian Havervall, Louisa Goumidi, Louisa Goumidi, Maria Farm, Maria Farm, Gaëlle Munsch, Gaëlle Munsch, Marine Germain, Marine Germain, Philip B. Smith, Philip B. Smith, Mun‐Gwan Hong, Mun‐Gwan Hong, Pierre Suchon, Pierre Suchon, Clément Naudin, Clément Naudin, Anne Boland, Anne Boland, David M. Smadja, David M. Smadja, Margareta Holmström, Margareta Holmström,

Preprint2020

The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis

Sergey Moiseev, Jiwon Lee, Anastasiia Zykova, N. Bulanov, Pavel Novikov, Eugeniy Gitel, Mayra Bulanova, E. S. Safonova, Jae Il Shin, Andreas Kronbichler, David Jayne

Article2020

The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis

Sergey Moiseev, Jiwon M. Lee, Anastasiia Zykova, N. Bulanov, Pavel Novikov, E P Gitel, Mayra Bulanova, E. S. Safonova, Jae Il Shin, Andreas Kronbichler, David Jayne

Article2009

aHUS-associated genetic complement abnormalities cause C3 deposition on endothelial cells: Protective effects of specific inhibitors of the alternative pathway of complement

Sara Gastoldi, Miriam Galbusera, Woodruff Emlen, V. Michael Holers, Federica Banterla, Roberta Donadelli, Giuseppe Remuzzi, Marina Noris

Severe COVID-19 is associated with hyperactivation of the alternative complement pathway

Discussion(0)

Related publications

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous thromboembolism and COVID-19 severity

The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis

The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis

aHUS-associated genetic complement abnormalities cause C3 deposition on endothelial cells: Protective effects of specific inhibitors of the alternative pathway of complement